FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557127908> ?p ?o ?g. }

• W2557127908 abstract "Abstract Monoclonal antibodies and chemotherapy can be effective, but not curative, therapy for non-Hodgkin s lymphoma (NHL). Rituximab acts by several mechanisms, including directly signaling apoptosis of CD20+ cells via the mitochondrial pathway involving caspase 9. Chemotherapy also activates this apoptotic pathway. TRAIL-R1 and -R2 signaling induces apoptosis via a pathway that activates caspase 8. Thus, we investigated the effects of agonistic monoclonal antibodies to TRAIL-R1 and -R2 on NHL cell lines (DoHH2, WSU-FSCCL and FC-TxFL2, each t(14;18)+, EBV-). TRAIL-R1 (HGS-ETR1) and -R2 (HGS-ETR2) antibodies were from Human Genome Sciences (Rockville, MD). FC-TxFL2 expressed the highest cell surface levels of TRAIL-R1 (DR4, target of HGS-ETR1) and TRAIL-R2 (DR5, target of HGS-ETR2). WSU-FSCCL expressed lower, but significant, levels of each. DoHH2 expressed dim TRAIL-R1 and the lowest levels of TRAIL-R2 of the 3 cell lines. IC50 (MTT assay after 72 hr incubation with antibody) was 0.25mcg/ml for WSU-FSCCL and FC-TxFL2 with either HGS-ETR1 or HGS-ETR2, while DoHH2 was minimally inhibited by either antibody. Both HGS-ETR1 and HGS-ETR2 antibodies induced dose dependent increases in apoptosis (annexin V assay) of WSU-FSCCL and FC-TxFL-2, but not DoHH2. Caspase activation (flow cytometry using fluorescent substrates; Western analysis) was seen 4–6 hr after antibody addition. As expected, caspases 3 and 8 were activated by both antibodies in the two sensitive cell lines. Caspase 9, however, was also activated. Thus, TRAIL-R1 and TRAIL-R2 antibody binding inhibits growth, induces apoptosis and activates caspases 3, 8 and 9 in NHL cells expressing the targets. The induction of caspase 9 suggests cross-talk between the extrinsic and intrinsic pathways, in which activation of caspase 8 leads to cleavage and translocation of bid, which in turn leads to activation of caspase 9, and ultimately caspase 3. We have confirmed that bid cleavage does occur in these NHL cells after HGS-ETR1 and HGS-ETR2 binding. We have further shown that both the pan-caspase inhibitor ZVAD and a specific caspase 8 inhibitor block HGS-ETR1 and HGS-ETR2 induced apoptosis. As predicted, a specific inhibitor of caspase 9 only partially blocks apoptosis. This suggests that combination of the agonist HGS-ETR1 and HGS-ETR2 antibodies with agents that act via the caspase 9 pathway would be rational combinations to test for therapeutic potential in NHL." @default.
• W2557127908 created "2016-11-30" @default.
• W2557127908 creator A5058502402 @default.
• W2557127908 creator A5069162526 @default.
• W2557127908 creator A5089854184 @default.
• W2557127908 date "2004-11-16" @default.
• W2557127908 modified "2023-09-30" @default.
• W2557127908 title "Antibodies to TRAIL Receptors R1 and R2 Induce Apoptosis in Non-Hodgkin’s Lymphoma Cells." @default.
• W2557127908 doi "https://doi.org/10.1182/blood.v104.11.3290.3290" @default.
• W2557127908 hasPublicationYear "2004" @default.
• W2557127908 type Work @default.
• W2557127908 sameAs 2557127908 @default.
• W2557127908 citedByCount "0" @default.
• W2557127908 crossrefType "journal-article" @default.
• W2557127908 hasAuthorship W2557127908A5058502402 @default.
• W2557127908 hasAuthorship W2557127908A5069162526 @default.
• W2557127908 hasAuthorship W2557127908A5089854184 @default.
• W2557127908 hasConcept C153911025 @default.
• W2557127908 hasConcept C159654299 @default.
• W2557127908 hasConcept C185592680 @default.
• W2557127908 hasConcept C190283241 @default.
• W2557127908 hasConcept C203014093 @default.
• W2557127908 hasConcept C2779338263 @default.
• W2557127908 hasConcept C31573885 @default.
• W2557127908 hasConcept C48297814 @default.
• W2557127908 hasConcept C502942594 @default.
• W2557127908 hasConcept C542903549 @default.
• W2557127908 hasConcept C54355233 @default.
• W2557127908 hasConcept C553184892 @default.
• W2557127908 hasConcept C55493867 @default.
• W2557127908 hasConcept C81885089 @default.
• W2557127908 hasConcept C86803240 @default.
• W2557127908 hasConcept C88634738 @default.
• W2557127908 hasConcept C98424977 @default.
• W2557127908 hasConceptScore W2557127908C153911025 @default.
• W2557127908 hasConceptScore W2557127908C159654299 @default.
• W2557127908 hasConceptScore W2557127908C185592680 @default.
• W2557127908 hasConceptScore W2557127908C190283241 @default.
• W2557127908 hasConceptScore W2557127908C203014093 @default.
• W2557127908 hasConceptScore W2557127908C2779338263 @default.
• W2557127908 hasConceptScore W2557127908C31573885 @default.
• W2557127908 hasConceptScore W2557127908C48297814 @default.
• W2557127908 hasConceptScore W2557127908C502942594 @default.
• W2557127908 hasConceptScore W2557127908C542903549 @default.
• W2557127908 hasConceptScore W2557127908C54355233 @default.
• W2557127908 hasConceptScore W2557127908C553184892 @default.
• W2557127908 hasConceptScore W2557127908C55493867 @default.
• W2557127908 hasConceptScore W2557127908C81885089 @default.
• W2557127908 hasConceptScore W2557127908C86803240 @default.
• W2557127908 hasConceptScore W2557127908C88634738 @default.
• W2557127908 hasConceptScore W2557127908C98424977 @default.
• W2557127908 hasLocation W25571279081 @default.
• W2557127908 hasOpenAccess W2557127908 @default.
• W2557127908 hasPrimaryLocation W25571279081 @default.
• W2557127908 hasRelatedWork W177206055 @default.
• W2557127908 hasRelatedWork W2120914366 @default.
• W2557127908 hasRelatedWork W2249326212 @default.
• W2557127908 hasRelatedWork W2348629719 @default.
• W2557127908 hasRelatedWork W2360124056 @default.
• W2557127908 hasRelatedWork W2370888976 @default.
• W2557127908 hasRelatedWork W2414051820 @default.
• W2557127908 hasRelatedWork W2940436098 @default.
• W2557127908 hasRelatedWork W3029638009 @default.
• W2557127908 hasRelatedWork W3198333935 @default.
• W2557127908 isParatext "false" @default.
• W2557127908 isRetracted "false" @default.
• W2557127908 magId "2557127908" @default.
• W2557127908 workType "article" @default.